

Fraxis Laser System Takes CO2 To The Next Level

Ilya Petrou, M.D.

Michael Naouri, M.D.
Dermatology and Laser Center
International Laser Skin Center
Nogent sur Marne and Paris, France

Widely viewed as a revolutionary treatment modality for skin rejuvenation, CO2 lasers have long been considered a cornerstone therapeutic device for numerous dermatologic indications. The Fraxis® laser system from Ilooda CO., LTD. takes this technology to the next level by offering effective and safe, high power CO2 fractional laser treatments, while minimizing the risk of adverse events such as post-inflammatory hyperpigmentation (PIH), regardless of skin type.

According to Michael Naouri, M.D., of the Dermatology and Laser Center in Nogent sur Marne, and the International Laser Skin Center in Paris, France, "the CO2 laser has experienced a revival since the introduction of fractional technology. In my opinion, the Fraxis laser is a new, high potential CO2 device that is versatile, usable in pulsed or fractional mode, reliable and very useful in both the dermatologic and aesthetic fields."

The Fraxis releases micro-sized laser beams that create micro-thermal zones (MTZ), resulting in a strong, dry ablation and mild thermal damage in the targeted skin. A uniform and stable beam quality, made possible by the 30 W radiofrequency (RF) metal tube, not only provides superior accuracy and precision to the fractional laser procedure, but results in safe treatments as well. The optimum beam size of the Fraxis helps to minimize the risk of PIH and downtime, in addition to maximizing the thermal effect with ablation.

Considered a solution for a widerange of aesthetic indications, the Fraxis effectively addresses skin rejuvenation, wrinkles, striae distensae, whitening, pore reduction, improvements in the tone and texture of skin, as well as the cosmesis of both acne and surgical scars. Beyond these commonly encountered cosmetic indications, this novel high power laser can also be a very useful tool in the treatment of numerous dermatologic indications.

To better understand the full therapeutic potential of the Fraxis system in the dermatologic practice, Dr. Naouri recently conducted a two month, single-center, retrospective study that included patients who benefited from a treatment with CO2 laser energy in continuous, pulsed or fractional mode, for an indication validated by at least one publication.

Results showed that 68 patients with 15 different skin issues were treated with the Fraxis device. Indications treated in surgical mode (continuous or pulsed) included 21 epidermal lesions (seborrheic keratosis, solar lentigines, verrucous papillomas of the eyelids, warts), one vascular lesion (ruby angioma), eight dermal lesions (xanthelasma, syringomas, sebaceous adenoma), four resistant warts and five laser incisions (cysts). In fractional mode 19 scars (acne, atrophic, burn) were treated, four photorejuvenation (periorbital, neck and hand laxity) treatments were performed, three striae distensae cases, one laser peel, and one penetration for pre-photodynamic therapy (PDT).

"Our study shows a high frequency of use (more than two patients per day) of the Fraxis in a wide variety of indications spanning both the medical and aesthetic fields. Moreover, the data confirms its important place in the dermatologist's practice for treating medical conditions. In my opinion, the Fraxis CO2 laser is a standard in terms of comfort and safety for the treatment of various benign indications, as well as profitability in aesthetic conditions," Dr. Naouri advised.

[VIEW ALL ARTICLES](#)